JP7332691B2 - 抗体の開発可能性が最大化された抗体ライブラリー - Google Patents

抗体の開発可能性が最大化された抗体ライブラリー Download PDF

Info

Publication number
JP7332691B2
JP7332691B2 JP2021523556A JP2021523556A JP7332691B2 JP 7332691 B2 JP7332691 B2 JP 7332691B2 JP 2021523556 A JP2021523556 A JP 2021523556A JP 2021523556 A JP2021523556 A JP 2021523556A JP 7332691 B2 JP7332691 B2 JP 7332691B2
Authority
JP
Japan
Prior art keywords
antibody
heavy chain
light chain
population
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021523556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531822A5 (https=
JP2021531822A (ja
Inventor
レイモン モートン ブラッドバリー アンドリュー
フランク エラスムス マイケル
テイシェイラ アンドレ
Original Assignee
スペシフィカ インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スペシフィカ インコーポレイティド filed Critical スペシフィカ インコーポレイティド
Publication of JP2021531822A publication Critical patent/JP2021531822A/ja
Publication of JP2021531822A5 publication Critical patent/JP2021531822A5/ja
Priority to JP2023129892A priority Critical patent/JP2023145778A/ja
Application granted granted Critical
Publication of JP7332691B2 publication Critical patent/JP7332691B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021523556A 2018-07-08 2019-07-08 抗体の開発可能性が最大化された抗体ライブラリー Active JP7332691B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023129892A JP2023145778A (ja) 2018-07-08 2023-08-09 抗体の開発可能性が最大化された抗体ライブラリー

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862695065P 2018-07-08 2018-07-08
US62/695,065 2018-07-08
US201962822671P 2019-03-22 2019-03-22
US62/822,671 2019-03-22
PCT/US2019/040843 WO2020014143A1 (en) 2018-07-08 2019-07-08 Antibody libraries with maximized antibody developability characteristics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023129892A Division JP2023145778A (ja) 2018-07-08 2023-08-09 抗体の開発可能性が最大化された抗体ライブラリー

Publications (3)

Publication Number Publication Date
JP2021531822A JP2021531822A (ja) 2021-11-25
JP2021531822A5 JP2021531822A5 (https=) 2022-11-04
JP7332691B2 true JP7332691B2 (ja) 2023-08-23

Family

ID=69102540

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523556A Active JP7332691B2 (ja) 2018-07-08 2019-07-08 抗体の開発可能性が最大化された抗体ライブラリー
JP2023129892A Pending JP2023145778A (ja) 2018-07-08 2023-08-09 抗体の開発可能性が最大化された抗体ライブラリー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023129892A Pending JP2023145778A (ja) 2018-07-08 2023-08-09 抗体の開発可能性が最大化された抗体ライブラリー

Country Status (5)

Country Link
US (8) US10954508B2 (https=)
EP (1) EP3833685A4 (https=)
JP (2) JP7332691B2 (https=)
CA (1) CA3106115A1 (https=)
WO (1) WO2020014143A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
US20230167165A1 (en) * 2021-07-07 2023-06-01 Specifica Inc. Antibody affinity maturation using natural liability-free cdrs
CA3244280A1 (en) * 2022-02-17 2023-08-24 Rules-Based Medicine Inc. SINGLE-DOMAIN ANTIBODY BANK WITH MAXIMIZED ANTIBODY DEVELOPMENT CHARACTERISTICS
WO2023232857A1 (en) * 2022-06-03 2023-12-07 Ichnos Sciences SA Common light chain antibody libraries
IL320284A (en) * 2022-10-18 2025-06-01 Tubulis Gmbh Novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
CN118496354A (zh) * 2023-02-15 2024-08-16 三优生物医药(上海)有限公司 包含共同轻链的抗体库、其制备方法及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170362306A1 (en) 2015-01-13 2017-12-21 Ewha University-Industry Collaboration Foundation Method for preparing novel antibody library and library prepared thereby
JP2021506976A (ja) 2017-12-18 2021-02-22 ディストリビューテッド バイオ， インコーポレイテッド 根本的に多様なヒト抗体ライブラリー

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322614A1 (en) 1995-06-07 2011-05-18 Life Technologies Corporation Recombinational cloning using engineered recombination sites
ATE421976T1 (de) 1999-05-18 2009-02-15 Dyax Corp Fab fragmentbibliotheken und verfahren für deren verwendung
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US20060160178A1 (en) 2003-11-17 2006-07-20 Jonathan Rothberg Methods of generating antibody diversity in vitro
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
JP5225069B2 (ja) * 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
PE20110385A1 (es) * 2008-07-18 2011-06-22 Bristol Myers Squibb Co Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170362306A1 (en) 2015-01-13 2017-12-21 Ewha University-Industry Collaboration Foundation Method for preparing novel antibody library and library prepared thereby
JP2021506976A (ja) 2017-12-18 2021-02-22 ディストリビューテッド バイオ， インコーポレイテッド 根本的に多様なヒト抗体ライブラリー

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nature Biotechnology, 2000, vol. 18, p. 852-856

Also Published As

Publication number Publication date
US20240384437A1 (en) 2024-11-21
US11920258B2 (en) 2024-03-05
WO2020014143A1 (en) 2020-01-16
US11254931B2 (en) 2022-02-22
US12351946B2 (en) 2025-07-08
US20210171936A1 (en) 2021-06-10
US12351945B2 (en) 2025-07-08
US12359346B2 (en) 2025-07-15
JP2021531822A (ja) 2021-11-25
US20240384439A1 (en) 2024-11-21
CA3106115A1 (en) 2020-01-16
US20200010828A1 (en) 2020-01-09
JP2023145778A (ja) 2023-10-11
EP3833685A1 (en) 2021-06-16
US12344959B2 (en) 2025-07-01
US20240240360A1 (en) 2024-07-18
US20240384440A1 (en) 2024-11-21
US20240229297A1 (en) 2024-07-11
US20210214720A1 (en) 2021-07-15
EP3833685A4 (en) 2022-08-17
US10954508B2 (en) 2021-03-23

Similar Documents

Publication Publication Date Title
JP7332691B2 (ja) 抗体の開発可能性が最大化された抗体ライブラリー
JP4753578B2 (ja) 合成抗体ファージライブラリー
CN101970730A (zh) 通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法
Griffiths Production of human antibodies using bacteriophage
US12258679B2 (en) Polyclonal mixtures of antibodies, and methods of making and using them
US12442107B2 (en) Single domain antibody libraries with maximized antibody developability characteristics
KR102194203B1 (ko) 항체 나이브 라이브러리의 생성 방법, 상기 라이브러리 및 그 적용(들)
JP7337850B2 (ja) 抗体ライブラリー及びこれを用いた抗体スクリーニング方法
US20230295271A1 (en) Methods and compositions for in vitro affinity maturation of monoclonal antibodies
KR20220026869A (ko) 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리
JP2024523730A (ja) 天然のライアビリティを含まないｃｄｒを使用した抗体親和性成熟
Yang Phage Display Technology: Design, Library Construction, and Panning Strategies for Antibody Development

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221025

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230727

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230810

R150 Certificate of patent or registration of utility model

Ref document number: 7332691

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350